TEVOGEN BIO HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9905 USD | +3.18% |
|
-0.95% | -91.10% |
| Apr. 26 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
| Apr. 26 | Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 163M |
|---|---|---|---|---|---|
| Net income 2022 | -22M | Net income 2023 | -60M | EV / Sales 2022 | - |
| Net Debt 2022 | 34.52M | Net Debt 2023 | 94.37M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-11.8
x | P/E ratio 2023 |
-4.56
x | Employees | 19 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 3.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.18% | ||
| 1 week | -0.95% | ||
| Current month | -0.95% | ||
| 1 month | -66.08% | ||
| 3 months | -81.35% | ||
| 6 months | -90.91% | ||
| Current year | -91.10% |
1 week
0.95
1.03
1 month
0.802.73
Current year
0.8021.09
1 year
0.8021.09
3 years
0.8021.09
5 years
0.8021.09
10 years
0.8021.09
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 0.9905 | +3.18% | 221,658 |
| 24-05-06 | 0.96 | -1.03% | 118,121 |
| 24-05-03 | 0.97 | -1.64% | 74,179 |
| 24-05-02 | 0.9862 | +1.67% | 88,731 |
| 24-05-01 | 0.97 | -3.00% | 183,138 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
| 1st Jan change | Capi. | |
|---|---|---|
| -91.10% | 163M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +48.77% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- TVGN Stock